NXERA PHARMA UK LIMITED
Get an alert when NXERA PHARMA UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£132m
Latest balance sheet
Net assets
£165m
Equity attributable
Employees
183
Average over period
Profit before tax
-£28m
Period ending 2023-12-31
Net assets
1-year trend · vs Health Care median
Accounts
1-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | Δ vs prior |
|---|---|---|---|
| Turnover | £28,310,880 | — | |
| Operating profit | -£33,740,459 | — | |
| Profit before tax | -£27,671,849 | — | |
| Net profit | -£25,685,560 | — | |
| Cash | £132,186,821 | — | |
| Total assets less current liabilities | £197,579,868 | — | |
| Net assets | £164,680,598 | — | |
| Equity | £164,680,598 | — | |
| Average employees | 183 | — | |
| Wages | £12,514,173 | — | |
| Directors' remuneration | £1,868,164 | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing's period length differs materially from the prior year. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 |
|---|---|---|
| Operating margin | -119.2% | |
| Net margin | -90.7% | |
| Return on capital employed | -17.1% | |
| Current ratio | 8.78x | |
| Interest cover | -43.36x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- NXERA PHARMA UK LIMITED 2024-04-02 → present
- HEPTARES THERAPEUTICS LIMITED 2007-06-04 → 2024-04-02
Audit & accounting basis
- Accounting basis
- FRS 101
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Accordingly, the Directors are of the opinion that the Company has sufficient funds to continue to meet any liabilities as they fall due in the period up to 31 July 2027 and therefore have prepared the financial statements on a going concern basis.”
Group structure
- NXERA PHARMA UK LIMITED · parent
- Heptares Therapeutics Zürich AG 100%
- Nxera Pharma Ireland Limited 100%
Significant events
- “On 14 January 2025, Neurocrine Biosciences Inc. completed an End of Phase 2 meeting with the US Food and Drug Administration for NBI-1117568 and indicated intention to initiate Phase 3 registrational studies in schizophrenia in H1 2025.”
- “On 25 March 2025, partner Tempero Bio, Inc., initiated a Phase 2 trial of TMP-301 for alcohol use disorder; this program was subsequently terminated by Tempero.”
- “On 2 June 2025, the Company achieved a development milestone under its multi-target collaboration and licence agreement with Eli Lilly and Company targeting diabetes and metabolic diseases, resulting in a payment to the Company.”
- “On 3 June 2025, Neurocrine dosed the first patient in its Phase 3 registrational program of NBI-'568 as a potential treatment for schizophrenia, resulting in a payment of US$15 million to the Company.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 22 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| NAKAFUJI, Mariko | Secretary | 2021-07-16 | — | — |
| CARGILL, Christopher Robert | Director | 2019-01-21 | Jan 1984 | Australian |
| CHONG, Candelle Wai-Yee | Director | 2023-03-30 | Oct 1989 | British |
| FOERCH, Patrik, Dr | Director | 2025-10-21 | Dec 1971 | British |
| JOHNSON, Kieran Roy Darren | Director | 2019-01-21 | May 1969 | British |
| NAKAFUJI, Mariko | Director | 2025-04-01 | Dec 1985 | Japanese |
Show 22 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BRIMBLECOMBE, Andrew | Secretary | 2019-01-21 | 2021-07-16 |
| CASDAGLI, Thomas Theodore | Secretary | 2007-07-05 | 2007-08-14 |
| INGLEBY NOMINEES LIMITED | Corporate Secretary | 2007-06-04 | 2007-07-05 |
| RESOLVE CAMBRIDGE LIMITED | Corporate Secretary | 2007-08-14 | 2009-05-22 |
| BAINS, Peter James Jonathan | Director | 2015-02-20 | 2016-07-21 |
| BARNES, Matthew Joseph | Director | 2022-03-24 | 2025-09-30 |
| BEDNARSKI, Eric, Dr | Director | 2012-03-27 | 2015-02-20 |
| BERRIMAN, John Edward | Director | 2007-07-20 | 2015-02-20 |
| CASDAGLI, Thomas Theodore | Director | 2007-07-05 | 2009-02-17 |
| DOOGAN, Declan, Dr | Director | 2015-02-20 | 2016-07-21 |
| HENDERSON, Richard, Dr | Director | 2007-07-20 | 2014-06-12 |
| KOENIG, Anja, Dr | Director | 2009-02-17 | 2015-02-20 |
| MARSHALL, Fiona Hamilton, Dr | Director | 2015-02-20 | 2018-02-28 |
| MARSHALL, Fiona Hamilton | Director | 2007-08-14 | 2009-02-17 |
| MURPHY, Martin Patrick, Dr | Director | 2007-07-05 | 2012-03-27 |
| PANDE, Atul, Dr | Director | 2014-12-01 | 2016-05-31 |
| PERLMUTTER, Roger M, Dr | Director | 2012-10-22 | 2013-04-03 |
| SOLARI, Roberto Celeste Ercole, Dr | Director | 2014-06-12 | 2016-05-31 |
| STEINMETZ, Ludwig Michael, Dr | Director | 2009-02-17 | 2015-02-20 |
| TASKER, Timothy Charles Gadsden, Dr | Director | 2018-02-28 | 2022-03-24 |
| WEIR, Malcolm, Dr | Director | 2007-07-05 | 2022-03-24 |
| INGLEBY HOLDINGS LIMITED | Corporate Director | 2007-06-04 | 2007-07-05 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mr Peter Jonathan Bains | Individual | Appoints directors (as firm), Significant influence (as firm) | 2016-04-06 | Ceased 2018-12-31 |
| Dr Malcolm Weir | Individual | Appoints directors (as firm), Significant influence (as firm) | 2016-04-06 | Ceased 2018-12-31 |
| Dr Fiona Hamilton Marshall | Individual | Appoints directors (as firm), Significant influence (as firm) | 2016-04-06 | Ceased 2018-02-28 |
Filing timeline
Last 20 of 168 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-10-29 MA Memorandum articles
- 2025-10-23 RESOLUTIONS Resolution
- 2024-04-02 CERTNM Certificate change of name company PDF
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-25 | AA | accounts | Accounts with accounts type full | |
| 2026-06-03 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2026-06-03 | PSC09 | persons-with-significant-control | Withdrawal of a person with significant control statement | |
| 2026-06-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-29 | MA | incorporation | Memorandum articles | |
| 2025-10-23 | RESOLUTIONS | resolution | Resolution | |
| 2025-10-21 | AP01 | officers | Appoint person director company with name date | |
| 2025-10-21 | TM01 | officers | Termination director company with name termination date | |
| 2025-10-17 | CH01 | officers | Change person director company with change date | |
| 2025-10-16 | CH01 | officers | Change person director company with change date | |
| 2025-08-01 | AA | accounts | Accounts with accounts type full | |
| 2025-06-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-04-25 | AP01 | officers | Appoint person director company with name date | |
| 2024-08-29 | AA | accounts | Accounts with accounts type full | |
| 2024-06-17 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-04-02 | CERTNM | change-of-name | Certificate change of name company | |
| 2023-08-03 | AA | accounts | Accounts with accounts type full | |
| 2023-05-30 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-04-18 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-06 | SH19 | capital | Capital statement capital company with date currency figure |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 11
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.